Nuvilex Associate's Patent Expansion Sets Stage for Treatment of HIV, Ebola, and SARS Virus
SILVER SPRING, Md.--(BUSINESS WIRE)--Dec 22, 2011 - Nuvilex, Inc. (OTCQB:NVLX), an emerging international biotechnology provider of cell and gene therapy solutions including encapsulation of live cells and services through their associate SG Austria, released information today about the therapeutic potential of the patent for treatment of HIV and Ebola viruses, Bird flu, SARS, and other infectious diseases.
This patent family provides for encapsulation and implantation of live cells producing proteins to treat specific diseases. Once implanted, live cells provide continuous production of the therapeutic protein needed, like antibodies or antibody-like molecules.
Substantial research has shown that the ability to have continuous production in the body avoids the rise and fall associated with standard injections, making this a commanding delivery method for treating many different diseases. The power of the use of the technology has already been demonstrated in a therapeutic animal model setting where production of a neutralising antibody led to protection against a lethal virus-induced disease, even when the infection was full-blown prior to treatment.
Nuvilex believes such diseases as diverse as HIV, Ebola, and other infectious or viral diseases are excellent candidates for such treatment.
For infectious diseases such as HIV, Ebola, West Nile, or the SARS virus, for which neutralizing already antibodies exist, even sudden-onset, life-threatening conditions have great potential for rapid and long-term treatment using encapsulation technology.
Anti-HIV neutralizing antibodies have been isolated by a number of researchers and two of these, b12 and VRC01, have recently been reported to completely protect against HIV in an animal model. The long term production of such antibodies from a depot of encapsulated live cells may improve the efficacy of such treatments.
Moreover, recent application of the cell encapsulation technology may prove to have a useful role for the treatment of life-threatening Bird flu (avian influenza) infections caused by the H5N1 influenza A virus that primarily infects birds, including poultry. Research since the highly publicized Bird flu outbreaks showed antibodies can neutralize the effects of the Avian influenza virus, making it another excellent encapsulation candidate.
Dr. Robert F. Ryan, President and CEO, commented, “The revenue potential from this family of patents is substantial. We have asked our analysts to establish a valuation for this family of patents, which we will disseminate to the investment community. We believe the ability to produce encapsulated cells producing proteins or antibodies to be a valuable asset for Nuvilex and should allow our larger new Nuvilex to expand our capabilities in the New Year. We are already working on this area and hope to move it forward farther in the coming year for diseases like HIV, Ebola virus, bird flu, and SARS.”
Nuvilex, Inc. (OTCQB:NVLX) is becoming an emerging international biotechnology provider of clinically useful therapeutic live encapsulated cells and services for encapsulating live cells for the research and medical communities. Substantial planning is yielding a stronger position and greater value of the assets of SG Austria that will be coming into Nuvilex. Our oncology offerings will include cancer treatments using the company's industry-leading live-cell encapsulation technology. Current consumer healthcare products carried by Nuvilex include BiaDiagnostics certified Gluten-Free Cinnergen™ and others to enhance a healthy lifestyle, cosmetic use, flu treatment, tattoo inks, antimicrobial and antinematodal agents.
Safe Harbor Statement
This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Contact: Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
Posted: December 2011